Keywords: positive, data, teva, agilect, addition, rasagiline, mesylate
Positive data for Teva's Agilect
Article | 13 September 2004
The addition of Agilect (rasagiline mesylate) to levodopa therapy inmoderate-to-advanced Parkinson's disease patients resulted in a reduction of tremor, a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
